Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Clinical trial NCT07121829 · TERMINATED

Trial details

NCT number: NCT07121829
Sponsor: Day One Biopharmaceuticals, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Melanoma Solid Tumor Pilocytic Astrocytoma Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Cancer MAP Kinase Family Gene Mutation RAS Mutation RAF Mutation MEK Mutation

Start date: 2022-05-02
Primary completion: 2024-12-18
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.